Sign up USA
Proactive Investors - Run By Investors For Investors

Lannett Company gets FDA nod for generic flu drug

"We expect to launch the product in time for the coming flu season,” said Arthur Bedrosian, Lannett chief executive.
flu patient
Its the first product to clear FDA approval after pharmacokinetic by DarmanTest

Generic drug manufacturer Lannett Company Inc (NYSE: LCI) is looking forward to the next flu season after securing approval for a new product, comparable to the Symmetrel branded treatment.

The Food and Drug Administration (FDA) has signed off Lannett’s Amantadine Hydrochloride Capsules, described as being the ‘therapeutic equivalent’ of the reference standard drug which is produced by Sandoz Pharmaceuticals.

"While this approval comes too late to benefit fiscal 2017, which ends later this month, we expect to launch the product in time for the coming flu season,” said Arthur Bedrosian, Lannett chief executive.

He also highlighted that the approval was approved in 15 months, and it represents the first product to be approved following bio-equivalency study at the company’s pharmacokinetic subsidiary, DarmanTest Laboratories.  

View full LCI profile View Profile

Lannett Company Timeline

Newswire
February 10 2011

Related Articles

Cells
May 17 2017
Revenues are on the rise and the group’s efforts to bring in new business is delivering.
1-Operation.jpg
January 18 2017
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off
cancer cells under a microscope
June 26 2017
The first system LIGHT system will be installed in its Harley Street facility, which is scheduled to be ready for installation by the first half of 2019
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use